Why did Regeneron report a net loss despite significant revenue growth?

Regeneron reported a net loss because the company is heavily investing in research and development. R&D expenses increased significantly in Q1 2008 to support its pipeline of product candidates, including late-stage trials for aflibercept and VEGF Trap-Eye, which leads to higher overall expenses exceeding the recognized revenue for the period. Additionally, ARCALYST™ product revenue has not yet been recognized due to accounting policies for deferred revenue.

How is Regeneron generating revenue, and what is the outlook for revenue recognition?

Regeneron's revenue is primarily generated from contract research and development activities related to its collaborations with sanofi-aventis and Bayer HealthCare, as well as technology licensing. For ARCALYST™, revenue recognition has been deferred because the company lacks historical data on returns and rebates. Revenue will be recognized when these factors can be reasonably estimated or the right of return no longer exists.

What is the company's current financial position and liquidity outlook?

Regeneron maintains a strong liquidity position, with $520.9 million in cash and cash equivalents at the end of Q1 2008. The company expects its existing capital resources, combined with anticipated funding from its collaborations, to be sufficient to meet operating needs through at least 2012, although it acknowledges the potential need for additional financing and the upcoming maturity of $200 million in convertible debt in October 2008.

REGN 10-Q Quarterly Report Q1 FY2008 — Revenue, Net Income, EPS

Q: What is the most significant recent product development for Regeneron?

The most significant recent development is the FDA approval and subsequent launch of ARCALYST™ (rilonacept) for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in late March 2008. This marks the company's first marketed product.

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported its first quarter 2008 financial results, showcasing significant revenue growth driven by its strategic collaborations, particularly with sanofi-aventis and Bayer HealthCare. Total revenues surged to $56.4 million, a substantial increase from $15.8 million in the prior year's quarter. This growth was primarily fueled by contract research and development revenue from these partnerships, along with technology licensing revenue. Despite the revenue increase, the company reported a net loss of $11.6 million ($0.15 per share) for the quarter, an improvement from the $29.9 million net loss ($0.46 per share) in Q1 2007, reflecting increased investment in research and development activities. The company achieved a significant milestone with the FDA approval and subsequent launch of ARCALYST™ (rilonacept) for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in late March 2008. However, due to a lack of historical return or rebate experience, no product sales revenue has been recognized yet for ARCALYST™, with revenue recognition deferred until these factors can be reasonably estimated. The company's cash position remains strong, with $520.9 million in cash and cash equivalents at the end of the quarter, bolstered by significant payments from collaborations. Looking ahead, Regeneron continues to invest heavily in its pipeline, with substantial R&D expenses anticipated, particularly for its late-stage programs including aflibercept (VEGF Trap) and VEGF Trap-Eye.

Key Highlights

1Total revenues increased significantly to $56.4 million in Q1 2008 from $15.8 million in Q1 2007, primarily driven by collaborations.
2Achieved FDA approval and launched ARCALYST™ (rilonacept) for CAPS in late March 2008.
3Reported a net loss of $11.6 million ($0.15/share) in Q1 2008, an improvement from a net loss of $29.9 million ($0.46/share) in Q1 2007.
4Cash and cash equivalents stood at $520.9 million at March 31, 2008, reflecting strong liquidity.
5Research and development expenses increased to $61.3 million in Q1 2008, up from $41.2 million in Q1 2007, indicating continued investment in pipeline development.
6No ARCALYST™ product sales revenue recognized in Q1 2008 due to deferral accounting for potential returns and rebates.
7Significant ongoing investment in late-stage clinical programs including aflibercept (oncology) and VEGF Trap-Eye (ophthalmology).

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2008

Summary

Key Highlights

Frequently Asked Questions